MX2022007441A - Inhibidores de proteína tirosina fosfatasa y sus métodos de uso. - Google Patents

Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.

Info

Publication number
MX2022007441A
MX2022007441A MX2022007441A MX2022007441A MX2022007441A MX 2022007441 A MX2022007441 A MX 2022007441A MX 2022007441 A MX2022007441 A MX 2022007441A MX 2022007441 A MX2022007441 A MX 2022007441A MX 2022007441 A MX2022007441 A MX 2022007441A
Authority
MX
Mexico
Prior art keywords
protein tyrosine
tyrosine phosphatase
methods
phosphatase inhibitors
ptpn1
Prior art date
Application number
MX2022007441A
Other languages
English (en)
Inventor
Hongyu Zhao
Andrew Bogdan
Jennifer M Frost
Philip R Kym
Xueqing Wang
Geoff T Halvorsen
Zhaoming Xiong
Roohollah Kazem Shiroodi
Christina Baumgartner
Jason R Abbott
Christos Economou
Elliot P Farney
Qingwei Zhang
Matthew O''connor
Original Assignee
Calico Life Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calico Life Sciences Llc filed Critical Calico Life Sciences Llc
Publication of MX2022007441A publication Critical patent/MX2022007441A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C07F9/65392—Five-membered rings containing two nitrogen atoms
    • C07F9/65397—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan en el presente documento compuestos, composiciones y métodos útiles para inhibir proteína tirosina fosfatasa, por ejemplo, proteína tirosina fosfatasa no receptora de tipo 2 (PTPN2) y/o proteína tirosina fosfatasa no receptora de tipo 1 (PTPN1) y para tratar enfermedades, trastornos y condiciones relacionadas que responden favorablemente al tratamiento con inhibidor de PTPN1 o PTPN2, por ejemplo, un cáncer o una enfermedad metabólica.
MX2022007441A 2019-12-18 2020-12-18 Inhibidores de proteína tirosina fosfatasa y sus métodos de uso. MX2022007441A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962949613P 2019-12-18 2019-12-18
PCT/US2020/066104 WO2021127499A1 (en) 2019-12-18 2020-12-18 Protein tyrosine phosphatase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022007441A true MX2022007441A (es) 2022-09-02

Family

ID=74195125

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007441A MX2022007441A (es) 2019-12-18 2020-12-18 Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.

Country Status (8)

Country Link
US (1) US20230019236A1 (es)
EP (1) EP4077291A1 (es)
JP (1) JP2023507774A (es)
CN (1) CN116348455A (es)
AU (1) AU2020407648A1 (es)
CA (1) CA3162069A1 (es)
MX (1) MX2022007441A (es)
WO (1) WO2021127499A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023086495A1 (en) * 2021-11-11 2023-05-19 Calico Life Sciences Llc Protein tyrosine phosphatase inhibitors and methods of use thereof
CA3236854A1 (en) * 2021-11-11 2023-05-19 Andrew Bogdan Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2024059041A1 (en) * 2022-09-13 2024-03-21 Kumquat Biosciences, Inc. Benzo-fused n-heterocycles and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US162A (en) 1837-04-17 Island
US5212A (en) 1847-07-31 Richard m
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
UA94921C2 (en) * 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
CR20210017A (es) * 2018-06-21 2021-11-03 Calico Life Sciences Llc Inhibidores de proteína tirosina fosfatosa y sus métodos de uso
CA3131894A1 (en) * 2019-03-14 2020-09-17 Calico Life Sciences Llc Protein tyrosine phosphatase inhibitors and methods of use thereof

Also Published As

Publication number Publication date
CA3162069A1 (en) 2021-06-24
US20230019236A1 (en) 2023-01-19
JP2023507774A (ja) 2023-02-27
AU2020407648A1 (en) 2022-06-30
CN116348455A (zh) 2023-06-27
EP4077291A1 (en) 2022-10-26
WO2021127499A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
CR20210516A (es) Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos
PH12020552228A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
MX2022007441A (es) Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.
JOP20210154B1 (ar) مثبطات kif18a
MX2021007104A (es) Inhibidores de kif18a.
MX2022001181A (es) Inhibidores de kif18a.
EA202091709A1 (ru) Ингибиторы днк-пк
MX2022016434A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MX2023002953A (es) Inhibidores de proteína tirosina fosfatasa y métodos para su uso.
PH12021551169A1 (en) Compositions and methods of modulating short-chain dehydrogenase activity
MX2020014303A (es) Inhibición de la proteína de union a creb (cbp).
CR20230362A (es) Inhibidores de cdk2 y métodos de uso de los mismos
MX2022002443A (es) Compuestos inhibidores de perk.
MX2021003992A (es) Inhibidores de la acido graso sintasa (fasn).
MX2021010829A (es) Inhibición de la proteína de unión al elemento de respuesta a adenosín monofosfato (amp) cíclica (creb).
MX2020013805A (es) Derivados de piridopirimidinona para uso como inhibidores de axl.
WO2024026484A3 (en) Cdk2 inhibitors and methods of using the same
WO2024026479A3 (en) Cdk2 inhibitors and methods of using the same
EA202190112A1 (ru) Ингибирование creb-связывающего белка (cbp)
EA202191523A1 (ru) Способы лечения видов рака, при которых сверхэкспрессируется whsc1, путем ингибирования активности setd2
TW202417449A (zh) Cdk2抑制劑及使用彼等之方法
EA201892360A1 (ru) Лечение нарушений, характеризующихся выпадением волос, с помощью дейтерированных ингибиторов jak
EA202090857A1 (ru) ПРИМЕНЕНИЕ ИНГИБИТОРОВ p38 ДЛЯ СНИЖЕНИЯ ЭКСПРЕССИИ DUX4